Similar to what was observed in psoriasis, PASI 100 improvements at 12 weeks were correlated with reduction of circulating IL-19 to normal levels at 4 weeks (one-way ANOVA p < 0.0001), with the majority of the poor PASI responders being in the placebo group (Fig. 4c). The gene discussed is IL19; the disease is psoriasis.